{"id":18644,"date":"2023-12-11T11:58:55","date_gmt":"2023-12-11T10:58:55","guid":{"rendered":"http:\/\/mabdesign.fr\/naobios-recoit-17-million-deuros-pour-soutenir-le-developpement-des-vaccins\/"},"modified":"2023-12-11T12:08:41","modified_gmt":"2023-12-11T11:08:41","slug":"naobios-receives-17-million-euros","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/","title":{"rendered":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development"},"content":{"rendered":"\n

Nantes, France, December 11, 2023 \u2013<\/strong> Naobios<\/strong>, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, today announces the receipt of a $1.87M (\u20ac1.7M) grant from the Bill & Melinda Gates Foundation in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process. To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development.<\/p>\n","protected":false},"author":2,"featured_media":18635,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-18644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-our-members"],"yoast_head":"\nNaobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign<\/title>\n<meta name=\"description\" content=\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-11T10:58:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-11T11:08:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"385\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"Ana-Sofia ANTUNES\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana-Sofia ANTUNES\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\"},\"author\":{\"name\":\"Ana-Sofia ANTUNES\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd\"},\"headline\":\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development\",\"datePublished\":\"2023-12-11T10:58:55+00:00\",\"dateModified\":\"2023-12-11T11:08:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\"},\"wordCount\":84,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif\",\"articleSection\":[\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\",\"name\":\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif\",\"datePublished\":\"2023-12-11T10:58:55+00:00\",\"dateModified\":\"2023-12-11T11:08:41+00:00\",\"description\":\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif\",\"width\":1024,\"height\":385},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd\",\"name\":\"Ana-Sofia ANTUNES\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g\",\"caption\":\"Ana-Sofia ANTUNES\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/ana-sofia-antunesmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign","description":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/","og_locale":"en_US","og_type":"article","og_title":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign","og_description":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.","og_url":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/","og_site_name":"MabDesign","article_published_time":"2023-12-11T10:58:55+00:00","article_modified_time":"2023-12-11T11:08:41+00:00","og_image":[{"width":1024,"height":385,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif","type":"image\/gif"}],"author":"Ana-Sofia ANTUNES","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Ana-Sofia ANTUNES","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/"},"author":{"name":"Ana-Sofia ANTUNES","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd"},"headline":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development","datePublished":"2023-12-11T10:58:55+00:00","dateModified":"2023-12-11T11:08:41+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/"},"wordCount":84,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif","articleSection":["Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/","url":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/","name":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif","datePublished":"2023-12-11T10:58:55+00:00","dateModified":"2023-12-11T11:08:41+00:00","description":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/12\/NAOBIOS-logo-quadri.gif","width":1024,"height":385},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/naobios-receives-17-million-euros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Naobios receives $1.87M (\u20ac1.7M) in support of vaccine development"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/c9d806b58aee7bc48c60b1f93e5b4bdd","name":"Ana-Sofia ANTUNES","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/062df62cc2ac391d996212d78eabdba3a6818c6616198c1e68bed19ffba5d93f?s=96&d=mm&r=g","caption":"Ana-Sofia ANTUNES"},"url":"https:\/\/mabdesign.fr\/en\/author\/ana-sofia-antunesmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/18644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=18644"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/18644\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/18635"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=18644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=18644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=18644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}